71
Participants
Start Date
June 30, 2007
Primary Completion Date
September 30, 2012
Study Completion Date
September 30, 2012
R-MEGACHOP
"* If PET + after third cycle: 2 cycles of R-IFE followed by PBSCT~* If PET - after third cycle: 3 additional cycles of R-MegaCHOP - R-MegaCHOP: cycles every 21 days RITUXIMAB Dosage: 375mg/m2, IV, day 1 CICLOPHOSPHAMIDE Dosage: 1500 mg/m2, IV, day 1 DOXORUBICIN Dosage: 65 mg/m2, IV, day 1 VINCRISTIN: Dosage 1.4 mg/m2 (max. 2.0 mg/m2, IV, day 1 PREDNISONE Dosage: 60 mg/m2, IV, day 1-5~R-IFE: 2 cycles every 21 days:~IFOSFAMIDE Dosage: continuous perfusion of 10 gr/m2/iv during 72 hours. Therefore, 3.33 gr/m2/corporal weight 24 hours day +1, +2 and +3.~ETOPOSIDE Dosage: total 900 mg/m2, IV, which is 150 mg/m2 during 12 hours (days +1, +2 and +3)."
Hospital de Jerez, Jerez de la Frontera
Hospital Clínico Univ. de Santiago, Santiago de Compostela
Complejo Hospitalario de Jaén, Jaén
Hospital Universitario La Princesa, Madrid
Hospital Universitario Gregorio Marañon, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Hospital Univ. Morales Meseguer, Murcia
Clínica Universitaria de Navarra, Pamplona
Hospital Universitario de Salamanca, Salamanca
Hospital Universitario de Canarias, San Cristóbal de La Laguna
Hospital Universitario Marques de Valdecilla, Santander
Hospital General de Segovia, Segovia
Hospital Universitario Río Hortega, Valladolid
Hospital Universitario Virgen de la Concha, Zamora
Hospital Clínico Lozano Blesa, Zaragoza
ICO- Hospital Duran i Reynals, L'Hospitalet de Llobregat
Hospital Univ. Son Dureta, Palma de Mallorca
Hospital Son Llàtzer, Palma de Mallorca
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
OTHER